P
PAVMED INC
NASDAQ: PAVM (PAVmed Inc.)
Last update: 11 hours ago8.67
-0.27 (-3.02%)
| Previous Close | 8.94 |
| Open | 8.94 |
| Volume | 15,328 |
| Avg. Volume (3M) | 1,058,535 |
| Market Cap | 7,987,541 |
| Price / Sales | 523.83 |
| Price / Book | 1.07 |
| 52 Weeks Range | |
| Earnings Date | 30 Mar 2026 |
| Profit Margin | 3,711.54% |
| Operating Margin (TTM) | -68,075.00% |
| Diluted EPS (TTM) | 3.46 |
| Quarterly Revenue Growth (YOY) | -99.20% |
| Total Debt/Equity (MRQ) | 22.57% |
| Current Ratio (MRQ) | 0.370 |
| Operating Cash Flow (TTM) | -22.03 M |
| Levered Free Cash Flow (TTM) | -19.74 M |
| Return on Assets (TTM) | -49.81% |
| Return on Equity (TTM) | 644.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | PAVmed Inc. | Bearish | Bearish |
AIStockmoo Score
-0.4
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.38 |
|
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 22.22% |
| % Held by Institutions | 7.05% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Byrne Asset Management Llc | 31 Dec 2025 | 126,400 |
| First Manhattan Co. Llc. | 31 Dec 2025 | 23,801 |
| Xml Financial, Llc | 31 Dec 2025 | 336 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities |
| 21 Jan 2026 | Announcement | Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard® |
| 30 Dec 2025 | Announcement | PAVmed Announces Reverse Stock Split |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |